Literature DB >> 24091162

Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.

Franco Locatelli1, Aurelie Bauquet, Giuseppe Palumbo, Francesca Moretta, Alice Bertaina.   

Abstract

In recent years, infusion of T-cell depleted hematopoietic stem cells from an HLA-haploidentical relative has been shown to represent a suitable and effective, alternative option in patients in need of an allograft who lack an HLA-identical relative. In particular, this type of allograft is associated with the enormous advantage of offering an immediate transplant treatment to virtually all pediatric patients without an HLA-matched donor, whether related or unrelated, or a suitable umbilical cord blood unit. Several studies have shown that in patients given a T-cell depleted transplant relevant part of the anti-leukemia effect is mediated by alloreactive (i.e. KIR/HLA mismatched) Natural Killer cells originated from donor hematopoietic stem cells. After infusion of positively selected hematopoietic stem cell, fully functioning Natural Killer cells emerge in the recipient peripheral blood, persisting over time, only several weeks after the allograft. We have developed a new method of T-cell depletion (based on the physical elimination of mature T cells carrying α and β chains of the T-cell receptor), which permits to maintain mature donor-derived alloreactive Natural Killer cells and γδ(+) T cells in the graft. We, thus, started a formal study in children with hematological disorders aimed at evaluating the safety and efficacy of this approach. Preliminary results on 60 children transplanted so far after this type of graft manipulation are particularly promising.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALL; AML; Allogeneic hematopoietic stem cell transplantation; GvHD; GvL; HSC; HSCT; MDS; NK; NK cell maturation; Selective T-cell depletion; T cell receptor; TCR; UCB; acute lymphoblastic leukemia; acute myeloid leukemia; graft-versus-host disease; graft-versus-leukemia; hematopoietic stem cell; hematopoietic stem cell transplantation; myelodysplastic syndromes; natural killer; umbilical cord blood; γδ(+) T cells

Mesh:

Substances:

Year:  2013        PMID: 24091162     DOI: 10.1016/j.imlet.2013.09.027

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  30 in total

Review 1.  How do I perform hematopoietic progenitor cell selection?

Authors:  Scott T Avecilla; Cheryl Goss; Sharon Bleau; Jo-Ann Tonon; Richard C Meagher
Journal:  Transfusion       Date:  2016-02-25       Impact factor: 3.157

Review 2.  Hematopoietic Stem Cells in Regenerative Medicine: Astray or on the Path?

Authors:  Albrecht M Müller; Sascha Huppertz; Reinhard Henschler
Journal:  Transfus Med Hemother       Date:  2016-07-26       Impact factor: 3.747

Review 3.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

4.  Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State.

Authors:  Bethany Powell Gray; Martin D Requena; Michael D Nichols; Bruce A Sullenger
Journal:  Cell Chem Biol       Date:  2019-12-23       Impact factor: 8.116

5.  Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.

Authors:  H J Im; K N Koh; J K Suh; S W Lee; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

6.  Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia.

Authors:  Ross Perko; Guolian Kang; Anusha Sunkara; Wing Leung; Paul G Thomas; Mari H Dallas
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-16       Impact factor: 5.742

Review 7.  T Cell-Depleted and T Cell-Replete HLA-Haploidentical Stem Cell Transplantation for Non-malignant Disorders.

Authors:  Alice Bertaina; Angela Pitisci; Matilde Sinibaldi; Mattia Algeri
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 8.  Allo-reactive T cells for the treatment of hematological malignancies.

Authors:  J H F Falkenburg; I Jedema
Journal:  Mol Oncol       Date:  2015-10-24       Impact factor: 6.603

9.  Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.

Authors:  Jessica Stokes; Emely A Hoffman; Yi Zeng; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Br J Haematol       Date:  2016-03-31       Impact factor: 6.998

10.  NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.

Authors:  Antonio Russo; Giacomo Oliveira; Sofia Berglund; Raffaella Greco; Valentina Gambacorta; Nicoletta Cieri; Cristina Toffalori; Laura Zito; Francesca Lorentino; Simona Piemontese; Mara Morelli; Fabio Giglio; Andrea Assanelli; Maria Teresa Lupo Stanghellini; Chiara Bonini; Jacopo Peccatori; Fabio Ciceri; Leo Luznik; Luca Vago
Journal:  Blood       Date:  2017-10-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.